International Textbook of Diabetes Mellitus, 4th Ed., Chapter 13 – Regulation of glucose metabolism in liver

References:

-

1. Newgard CB: Regulation of glucose metabolism in the liver. In: *International Textbook of Diabetes Mellitus*. John Wiley & Sons, Ltd., 2003.
2. Lavoisier A: Oeuvres de Lavoisier, Oeuvres. In: Bret P (ed.). *Académie des Sciences*, 1997, pp. 34–36.
3. Young FG: Claude Bernard and the discovery of glycogen: a century of retrospect. *BMJ* 1957;1(5033):1431 – 1437.
4. Roth J, Qureshi S, Whitford I, et al: Insulin's discovery: new insights on its ninetieth birthday. *Diabetes/Metabolism Research and Reviews* 2012;28(4):293 – 304.
5. Sutherland EW, Robison GA: The role of cyclic AMP in the control of carbohydrate metabolism. *Diabetes* 1969;18(12):797 – 819.
6. Wasserman DH: Four grams of glucose. *American Journal of Physiology — Endocrinology and Metabolism* 2009;296(1):E11 – 21.
7. Wahren J, Ekberg K: Splanchnic regulation of glucose production. *Annual Review of Nutrition* 2007;27:329 – 345.
8. DeFronzo R, Tobin J, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *American Journal of Physiology — Endocrinology and Metabolism* 1979;237(3):E214 – 223.
9. Basu R, Chandramouli V, Dicke B, et al: Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. *Diabetes* 2005;54(7):1942–1948.
10. Landau BR: Methods for measuring glycogen cycling. *American Journal of Physiology — Endocrinology and Metabolism* 2001;281(3):E413 – 419.
11. Landau BR, Wahren J, Chandramouli V, etal: Contributions of gluconeogenesis to glucose production in the fasted state. *Journal of Clinical Investigation* 1996;98(2):378 – 385.
12. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS: Glycogen and its metabolism: some new developments and old themes. *Biochemical Journal* 2012;441(3):763–787.
13. Wan M, Leavens KF, Hunter RW, et al: A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. *Cell Metabolism* 2013;18(1):99–105.
14. Petersen KF, Laurent D, Rothman DL, et al: Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. *Journal of Clinical Investigation* 1998;101(6):1203–1209.
15. Pilkis SJ, Granner DK: Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. *Annual Review of Physiology* 1992;54(1):885 – 909.

16. Chinkes DL, Wolfe RR: *Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis*, 2nd edn. Hoboken, NJ: John Wiley & Sons, Inc., 2005.
17. Landau BR, Wahren J, Previs SF, et al: Glycerol production and utilization in humans: sites and quantitation. *American Journal of Physiology* 1996;271(6 Pt 1):E1110 – 1117.
18. Chevalier S, Burgess SC, Malloy CR, et al: The greater contribution of gluconeogenesis to glucose production in obesity is related to increased whole-body protein catabolism. *Diabetes* 2006;55(3):675 – 681.
19. Hanson RW, Patel YM: Phosphoenolpyruvatecarboxykinase (GTP): the gene and the enzyme. *Advances in Enzymology and Related Areas of Molecular Biology* 1994;69:203–281.
20. Mendez-Lucas A, Duarte JA,SunnyNE,etal:PEPCK-M expression in mouse liver potentiates, not replaces, PEPCK-C mediated gluconeogenesis. *Journal of Hepatology* 2013;59(1):105–113.
21. Altarejos JY, Montminy M: CREB and the CRTC co-activators:sensors for hormonal and metabolic signals. *Nature Reviews Molecular Cell Biology* 2011;12(3):141–151.
22. Lin HV, Accili D: Hormonal regulation of hepatic glucose production in health and disease. *Cell Metabolism* 2011;14(1):9–19.
23. Leavens KF, Birnbaum MJ: Insulin signaling to hepatic lipid metabolism in health and disease. *Critical Reviews in Biochemistry and Molecular Biology* 2011;46(3):200 – 215.
24. Hasenour CM, Berglund ED, Wasserman DH: Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. *Molecular and Cellular Endocrinology* 2013;366(2):152 – 162.
25. Hall RK, Granner DK: Insulin regulates expression of metabolic genes through divergent signaling pathways. *Journal of Basic and Clinical Physiology and Pharmacology* 1999;10(2):119 – 133.
26. Chakravarty K, Cassuto H, Reshef L, et al: Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. *Critical Reviews in Biochemistry & Molecular Biology* 2005;40(3):129 – 154.
27. Park EA, Roesler WJ, Liu J, et al: The role of the CCAAT/enhancer-binding protein in the transcriptional regulation of the gene for phosphoenolpyruvate carboxykinase (GTP). *Molecular and Cellular Biology* 1990;10(12):6264-72.
28. Lu M, Wan M, Leavens KF, et al: Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. *Nature Medicine* 2012;18(3):388 – 395.
29. Cheng Z, Guo S, Copps K, et al: Foxo1 integrates insulin signaling with mitochondrial function in the liver. *Nature Medicine* 2009;15(11):1307 – 1311.
30. Lin J, Handschin C, Spiegelman BM: Metabolic control through the PGC-1 family of transcription coactivators. *Cell Metabolism* 2005;1(6):361 – 370.

31. Yoon JC, Puigserver P, Chen G, et al: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 2001;413(6852):131 – 138.
32. Burgess SC, Leone TC, Wende AR, et al: Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice. *The Journal of Biological Chemistry* 2006;281(28):19000 – 19008.
33. Sugden MC, Holness MJ: Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. *Archives of Physiology and Biochemistry* 2006;112(3):139 – 149.
34. Groen AK, van Roermund CW, Vervoorn RC, Tager JM: Control of gluconeogenesis in rat liver cells. *Flux control coefficients of the enzymes in the gluconeogenic pathway in the absence and presence of glucagon. Biochemical Journal* 1986;237(2):379 – 389.
35. Adina-Zada A, Zeczycki TN, St Maurice M, et al: Allosteric regulation of the biotin-dependent enzyme pyruvate carboxylase by acetyl-CoA. *Biochemical Society Transactions* 2012;40(3):567–572.
36. Landau BR, Schumann WC, Chandramouli V, et al: 14C-labeled propionate metabolism in vivo and estimates of hepatic gluconeogenesis relative to Krebs cycle flux. *American Journal of Physiology — Endocrinology and Metabolism* 1993;265(4): E636 – E647.
37. Landau BR, Chandramouli V, Schumann WC, et al: Estimates of Krebs cycle activity and contributions of gluconeogenesis to hepatic glucose production in fasting healthy subjects and IDDM patients. *Diabetologia* 1995;38(7):831–838.
38. Newsholme EA, Gevers W: Control of glycolysis and gluconeogenesis in liver and kidney cortex. *Vitamins and Hormones* 1967;25:1 – 87.
39. Pilkis SJ, Claus TH, Riou JP, Park CR: Possible role of pyruvate kinase in the hormonal control of dihydroxyacetone gluconeogenesis in isolated heptatocytes. *Metabolism: Clinical and Experimental* 1976;25(11 Suppl 1):1355–1360.
40. Friedman B, Goodman EH, Jr,, Saunders HL, et al: Estimation of pyruvate recycling during gluconeogenesis in perfused rat liver. *Metabolism: Clinical and Experimental* 1971;20(1):2–12.
41. Burgess SC, Jeffrey FMH, Storey C, et al: Effect of murine strain on metabolic pathways of glucose production after brief or prolonged fasting. *American Journal of Physiology — Endocrinology and Metabolism* 2005;289(1):E53 – 61.
42. Jin ES, Uyeda K, Kawaguchi T, et al: Increased hepatic fructose 2,6-bisphosphate after an oral glucose load does not affect gluconeogenesis. *Journal of Biological Chemistry* 2003;278(31):28427 – 28433.
43. McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes* 2002;51(1):7 – 18.

44. Williamson JR, Kreisberg RA, Felts PW: Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. *PNAS* 1966;56(1):247 – 254.
45. Roden M, Stingl H, Chandramouli V, et al: Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. *Diabetes* 2000;49(5):701–707.
46. Foretz M, Hebrard S, Leclerc J, etal: Metformin inhibits hepaticgluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *Journal of Clinical Investigation* 2010;120(7):2355 – 2369.
47. El-Mir MY, Nogueira V, Fontaine E, et al: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *The Journal of Biological Chemistry* 2000;275(1):223 – 228.
48. Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* 2005;310(5754):1642–1646.
49. Jahoor F, Peters EJ, Wolfe RR: The relationship between gluconeogenic substrate supply and glucose production in humans. *American Journal of Physiology* 1990;258(2, Pt 1):E288–E296.
50. Wolfe BM, Culebras JM, Aoki TT, et al: The effects of glucagon on protein metabolism in normal man. *Surgery* 1979;86(2):248 – 257.
51. Michael MD, Kulkarni RN, Postic C, et al: Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Molecular Cell* 2000;6(1):87 – 97.
52. Haas JT, Miao J, Chanda D, et al: Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. *Cell Metabolism* 2012;15(6):873 – 884.
53. Buettner C, Patel R, Muse ED, et al: Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. *Journal of Clinical Investigation* 2005;115(5):1306–1313.
54. Okamoto H, Obici S, Accili D, Rossetti L: Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. *Journal of Clinical Investigation* 2005;115(5):1314–1322.
55. Ramnanan CJ, Edgerton DS, Rivera N, etal: Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. *Diabetes* 2010;59(6):1302–1311.
56. Mittelman SD, Fu Y-Y, Rebrin K, et al: Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. *Journal of Clinical Investigation* 1997;100(12):3121 – 3130.
57. Satapati S, He T, Inagaki T, et al: Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. *Diabetes* 2008;57(8):2012 – 2021.

58. Kucejova B, Sunny NE, Nguyen AD, et al: Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. *Oncogene* 2011;30(18):2147–2160.
59. Hardie DG: AMP-activated protein kinase — an energy sensor that regulates all aspects of cell function. *Genes & Development* 2011;25(18):1895 – 1908.
60. Verdin E, Hirschey MD, Finley LWS, Haigis MC: Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. *Trends in Biochemical Sciences* 2010;35(12):669 – 675.
61. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metabolism* 2005;1(1):15 – 25.
62. Jäger S, Handschin C, St-Pierre J, Spiegelman BM: AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. *PNAS* 2007;104(29):12017 – 12022.
63. Sugden MC, Howard RM, Munday MR, Holness MJ: Mechanisms involved in the coordinate regulation of strategic enzymes of glucose metabolism. *Advances in Enzyme Regulation* 1993;33:71 – 95.
64. Dobrzyn P, Dobrzyn A, Miyazaki M,etal:Stearoyl-Co Adesaturase 1 deficiency increases fatty acid oxidation by activating AMP- activated protein kinase in liver. *PNAS* 2004;101(17):6409–6414.
65. Ellingson WJ, Chesser DG, Winder WW: Effects of 3-phosphoglycerate and other metabolites on the activation of AMP-activated protein kinase by LKB1-STRAD-MO25. *American Journal of Physiology — Endocrinology and Metabolism* 2007;292(2):E400 – 407.
66. Berglund ED, Lee-Young RS, Lustig DG, etal: Hepatic energy state is regulated by glucagon receptor signaling in mice. *Journal of Clinical Investigation* 2009;119(8):2412–2422.
67. Hirschey MD, Shimazu T, Goetzman E, etal: SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature* 2010;464(7285):121–125.
68. Moore MC, Coate KC, Winnick JJ, et al: Regulation of hepatic glucose uptake and storage in vivo. *Advances in Nutrition* 2012;3(3):286 – 294.
69. Matschinsky FM, Zelent B, Doliba NM, et al: *Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects*. Diabetes: *Perspectives in Drug Therapy*. Springer, 2011, pp. 357–401.
70. Andreone TL, Printz RL, Pilkis SJ, et al: The amino acid sequence of rat liver glucokinase deduced from cloned cDNA. *The Journal of Biological Chemistry* 1989;264(1):363–369
71. Iynedjian PB, Pilot PR, Nouspikel T, et al: Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. *PNAS* 1989;86(20):7838–7842.
72. Froguel P, Vaxillaire M, Sun F, et al: Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. *Nature* 1992;356(6365):162–164.

73. Velho G, Petersen KF, Perseghin G, et al: Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. *Journal of Clinical Investigation* 1996;98(8):1755–1761.
74. Matschinsky FM: Assessing the potential of glucokinase activators in diabetes therapy. *Nature Reviews Drug Discovery* 2009;8(5):399 – 416.
75. Ferre T, Riu E, Franckhauser S, et al: Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. *Diabetologia* 2003;46(12):1662–1668.
76. Matschinsky FM: GKAs for diabetes therapy:why no clinically useful drug after two decades of trying? *Trends in Pharmacological Sciences* 2013;34(2):90–99.
77. Mutel E, Abdul-Wahed A, Ramamonjisoa N, etal: Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. *Journal of Hepatology* 2011;54(3):529–537.
78. O'Doherty RM, Jensen PB, Anderson P, et al: Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen. *Journal of Clinical Investigation* 2000;105(4):479 – 488.
79. Shulman GI, Cline G, Schumann WC, et al: Quantitative comparison of pathways of hepatic glycogen repletion in fed and fasted humans. *American Journal of Physiology* 1990;259 (3 Pt 1):E335 – 341.
80. von Wilamowitz-Moellendorff A, Hunter RW, Garcia-Rocha M, et al: Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis. *Diabetes* 2013;62(12):4070 – 4082.
81. Newgard CB, Brady MJ, O'Doherty RM, Saltiel AR: Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. *Diabetes* 2000;49(12):1967–1977.
82. Ring DB, Johnson KW, Henriksen EJ, et al: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. *Diabetes* 2003;52(3):588 – 595.
83. Treadway JL, Mendys P, Hoover DJ: Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. *Expert Opinion on Investigational Drugs* 2001;10(3):439–454.
84. Van Schaftingen E, HueL, Hers HG: Fructose2,6-bisphosphate,the probable structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. *Biochemical Journal* 1980;192(3):897–901.
85. Pilkis SJ, El-Maghrabi MR, Pilkis J, etal: Fructose2,6-bisphosphate. *A new activator of phosphofructokinase. The Journal of Biological Chemistry* 1981;256(7):3171–3174.
86. Uyeda K, Furuya E, Sherry AD: The structure of "activation factor" for phosphofructokinase. *The Journal of Biological Chemistry* 1981;256(16):8679 – 8684.

87. Pilkis SJ, Chrisman T, Burgress B, etal: Rathepatic6-phosphofructo 2-kinase/fructose 2,6-bisphosphatase: a unique bifunctional enzyme. *Advances in Enzyme Regulation* 1983;21:147–173.
88. Murray KJ, El-Maghrabi MR, Kountz PD, et al: Amino acid sequence of the phosphorylation site of rat liver 6-phosphofructo-2- kinase/fructose-2,6-bisphosphatase. *The Journal of Biological Chemistry* 1984;259(12):7673–7681.
89. Nishimura M, Uyeda K: Purification and characterization of a novel xylulose 5-phosphate-activated protein phosphatase catalyzing dephosphorylation of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. *The Journal of Biological Chemistry* 1995;270(44): 26341 – 26346.
90. Wu C, Kang J, Peng L, et al: Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. *Cell Metabolism* 2005;2(2):131–140.
91. Ekman P ,Dahlqvist U, Humble E, etal: Comparative kinetic studies on the L-type pyruvate kinase from rat liver and the enzyme phosphorylated by cyclic 3', 5'-AMP-stimulated protein kinase. *Biochimica et Biophysica Acta* 1976;429(2):374–382.
92. Harris RA, Bowker-Kinley MM, Huang B, et al: Regulation of the activity of the pyruvate dehydrogenase complex. *Advances in Enzyme Regulation* 2002;42:249–259.

Horton JD, Goldstein JL, Brown MS:SREBPs:activators of the complete program of cholesterol and fatty acid synthesis in the liver. *Journal of Clinical Investigation* 2002;109(9):1125–1131.